Stock Ratings / Health Care / CRVS / options

PHAR (58) IVA (61) ALMS (23) OBX (39) ⌘ Pro Terminal →

Corvus Pharmaceuticals Inc. (CRVS) Options Positioning, Max Pain & Unusual Sweeps

$10.23 -2.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.16

Corvus Pharmaceuticals Inc. (CRVS) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $860.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.16 (-0.69%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRVS)Realized 20D OHLCV Swing Band: ±12.3%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY CRVS SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 39.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$10.52-9.5% Next Q

Q2 (-2Q)

Grade E$9.52+10.6% Next Q

Q3 (-1Q)

Grade E$10.53-2.8% Next Q

Current

Grade E$10.23-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRVS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRVS currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.94) and Max Pain ($10.74) forces dealer call-delta covering toward $28.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRVS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRVS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRVS)

✓Walkthrough of CRVS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.65%▼ DESCENDING CHANNEL

2026-10-30O $10.09H $10.37L $9.78C $10.23VOL 845.1K

RES: $14.40SUP: $8.49SMA50: $11.94SMA200: $14.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRVS Butterfly Map → + Track CRVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRVS)

Health Care Rank #912 of 1016 ⚔️ PHAR vs CRVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRVS vs. PHAR, IVA, ALMS, OBX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Corvus Pharmaceuticals Inc. (CRVS) ranks #912 by composite RQD confidence (31/100, grade E) and #380 by equity capitalization ($860.6M). Within this direct 5-issuer industry benchmark cohort, CRVS leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CRVS at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRVS ACTIVE Corvus Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-2.76%	$860.6M	Benchmark Subject
PHAR Pharming Group N.V. ADS each representing 10	D+	58/100	—	—	—	-1.06%	$856.7M	/phar-vs-crvs →
IVA Inventiva S.A. American Depository Shares	C-	61/100	—	—	—	+0.54%	$881.3M	/iva-vs-crvs →
ALMS Alumis Inc.	E	23/100	—	—	-35.0%	-3.37%	$891.8M	/alms-vs-crvs →
OBX Obsidian Therapeutics Inc.	D-	39/100	—	—	-35.0%	-0.48%	$896.9M	/obx-vs-crvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001626971

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corvus Pharmaceuticals Inc. (CRVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.3M, operating cash flow of -$32.8M, and free cash flow of -$33.0M (-29.7% YoY). On the balance sheet, CRVS closed FY2025 with $71.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$15.3M	-$32.8M	-$33.0M	$71.1M	—
FY2024 (FY)	2024-12-31	$0	-$62.3M	-$25.4M	-$25.4M	$68.9M	—
FY2023 (FY)	2023-12-31	$0	-$27.0M	-$23.9M	-$23.9M	—	—

3. CRVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.23 (-2.76% 1D, market cap $860.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVS ranks #912 in composite RQD confidence.

How does CRVS compare to PHAR and IVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVS carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHAR (Pharming Group N.V. ADS each representing 10) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $856.7M) and IVA (Inventiva S.A. American Depository Shares) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, CRVS leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRVS?

Per CRVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626971), Corvus Pharmaceuticals Inc. generated $0 in revenue, -$15.3M in net income, and -$33.0M in free cash flow against $71.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRVS trading relative to its 50-day, 200-day, and 52-week technical levels?

CRVS last traded at $10.23 (-2.76% on volume of 852,696 shares), positioning the stock -14.32% below its 50-day simple moving average ($11.94) and -29.16% below its 200-day simple moving average ($14.44). Across its 52-week range of $6.39 to $26.95, CRVS sits at the 18.7% percentile with a 14-day RSI of 39.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($8.97 to $11.49).